Evaluation of calprotectin and ischemia-modified albumin serum levels as biomarkers to measure disease activity in Behçet’s disease

Egyptian Rheumatology and Rehabilitation

Table 3 Comparison of the laboratory findings among the groups

	Active BD group (32 patients)	Inactive BD group (28 patients)	Control group (60 individuals)	P1	P2	P3
ESR (mm) (median [IQR])	45.0 [21.0]	40.0 [29.0]	21.0 [16.0]	0.013	< 0.001	< 0.001
CRP (mg/dl) (median [IQR])	34.1 [29.1]	24.9 [15.4]	3.4 [3.7]	0.035	< 0.001	< 0.001
hs-CRP (mg/dl) (median [IQR])	9.3 [7.7]	7.9 [9.8]	1.8 [1.6]	0.031	< 0.001	< 0.001
IMA (ABSU) (median [IQR])	0.52 [0.26]	0.45 [0.22]	0.36 [0.28]	0.013	< 0.001	0.002
Calprotectin (μg/ml) (median [IQR])	5.0 [1.1]	4.8 [0.7]	3.4 [0.4]	0.108	< 0.001	< 0.001

P1, comparison between the active BD group and inactive BD group; P2, comparison between the active BD group and control group; P3 comparison between the inactive BD group and control group
ABSU absorbance units, hs-CRP, high sensitive CRP; IMA ischemia-modified albumin, IQR interquartile range
Statistical test, one-way ANOVA
Significance considered with P ≤ 0.05